$IRME
IR-Med, Inc. Stock $irme

$irme Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223041051 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$771.0K	$728.0K	$1.534M
YoY Change	-49.74%	78.43%
% of Gross Profit
Research & Development	$491.0K	$469.0K	$528.0K
YoY Change	-7.01%	0.21%
% of Gross Profit
Depreciation & Amortization	$0.00	$13.00K	$0.00
YoY Change		30.0%
% of Gross Profit
Operating Expenses	$1.262M	$1.197M	$2.062M
YoY Change	-38.8%	36.64%
Operating Profit		-$1.197M
YoY Change		36.64%
Interest Expense	-$9.000K	$18.00K	-$28.00K
YoY Change	-67.86%	-10.0%
% of Operating Profit
Other Income/Expense, Net		$18.00K
YoY Change		-10.0%
Pretax Income	-$1.271M	-$1.179M	-$2.090M
YoY Change	-39.19%	37.73%
Income Tax
% Of Pretax Income
Net Earnings	-$1.271M	-$1.179M	-$2.090M
YoY Change	-39.19%	37.73%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.02
Diluted Earnings Per Share	-$0.02	-$0.02	-$0.03
COMMON SHARES
Basic Shares Outstanding	69.92M shares	69.83M shares	68.72M shares
Diluted Shares Outstanding		68.84M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$767.0K	$1.524M	$3.002M
YoY Change	-74.45%	-59.75%
Cash & Equivalents	$767.0K	$1.524M	$3.002M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses	$30.00K		$12.00K
Receivables	$81.00K	$83.00K	$55.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$848.0K	$1.607M	$3.057M
YoY Change	-72.26%	-58.46%	6.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$56.00K	$55.00K	$71.00K
YoY Change	-21.13%	-21.43%	129.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$11.00K	$11.00K	$11.00K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$151.0K	$166.0K	$237.0K
YoY Change	-36.29%	-34.65%	288.52%
TOTAL ASSETS
Total Short-Term Assets	$848.0K	$1.607M	$3.057M
Total Long-Term Assets	$151.0K	$166.0K	$237.0K
Total Assets	$999.0K	$1.773M	$3.294M
YoY Change	-69.67%	-57.0%	11.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$64.00K	$407.0K	$500.0K
YoY Change	-87.2%	24.09%
Accrued Expenses	$160.0K		$132.0K
YoY Change	21.21%		-5.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$152.0K	$162.0K
YoY Change	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$473.0K	$559.0K	$662.0K
YoY Change	-28.55%	70.43%	67.59%
LONG-TERM LIABILITIES
Long-Term Debt	$161.0K	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$0.00	$2.000K	$40.00K
YoY Change	-100.0%	-96.55%
Total Long-Term Liabilities	$161.0K	$2.000K	$40.00K
YoY Change	302.5%	-99.08%	-77.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$473.0K	$559.0K	$662.0K
Total Long-Term Liabilities	$161.0K	$2.000K	$40.00K
Total Liabilities	$634.0K	$561.0K	$702.0K
YoY Change	-9.69%	2.94%	22.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$14.84M	-$13.57M	-$9.930M
YoY Change	49.44%	73.06%	91.11%
Common Stock	$69.00K	$69.00K	$68.00K
YoY Change	1.47%	1.47%	6.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$365.0K	$1.212M	$2.592M
YoY Change
Total Liabilities & Shareholders Equity	$999.0K	$1.773M	$3.294M
YoY Change	-69.67%	-57.0%	11.93%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q4
OPERATING ACTIVITIES
Net Income	-$1.271M	-$1.179M	-$2.090M
YoY Change	-39.19%	37.73%
Depreciation, Depletion And Amortization	$0.00	$13.00K	$0.00
YoY Change		30.0%
Cash From Operating Activities	-$754.0K	-$1.578M	-$779.0K
YoY Change	-3.21%	-39.21%
INVESTING ACTIVITIES
Capital Expenditures	$1.000K	$1.000K	$2.000K
YoY Change	-50.0%	-97.92%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$1.000K	-$1.000K	-$2.000K
YoY Change	-50.0%	-98.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	1.000M	0.000
YoY Change		-72.41%
NET CHANGE
Cash From Operating Activities	-754.0K	-1.578M	-779.0K
Cash From Investing Activities	-1.000K	-1.000K	-2.000K
Cash From Financing Activities	0.000	1.000M	0.000
Net Change In Cash	-755.0K	-579.0K	-781.0K
YoY Change	-3.33%	-159.57%
FREE CASH FLOW
Cash From Operating Activities	-$754.0K	-$1.578M	-$779.0K
Capital Expenditures	$1.000K	$1.000K	$2.000K
Free Cash Flow	-$755.0K	-$1.579M	-$781.0K
YoY Change	-3.33%	-40.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001839133
	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-56492
	dei	Entity Registrant Name EntityRegistrantName	IR-Med, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-4516398
	dei	Entity Address Address Line1 EntityAddressAddressLine1	ZHR Industrial Zone
	dei	Entity Address City Or Town EntityAddressCityOrTown	Rosh Pina
	dei	Entity Address Country EntityAddressCountry	IL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	1231400
	dei	City Area Code CityAreaCode	972
	dei	Local Phone Number LocalPhoneNumber	4-655-5054
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	IRME
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	69924240	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1524000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3002000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	83000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	55000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	1607000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	3057000	usd
CY2023Q3	IRME	Long Term Restricted Deposit LongTermRestrictedDeposit	11000	usd
CY2022Q4	IRME	Long Term Restricted Deposit LongTermRestrictedDeposit	11000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	100000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	155000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	55000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	71000	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	166000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	237000	usd
CY2023Q3	us-gaap	Assets Assets	1773000	usd
CY2022Q4	us-gaap	Assets Assets	3294000	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	407000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	500000	usd
CY2023Q3	us-gaap	Loans Payable Current LoansPayableCurrent	152000	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	162000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	559000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	662000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	40000	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	40000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	561000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	702000	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69873424	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69873424	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68808970	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68808970	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	69000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	68000	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14711000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12454000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13568000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9930000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1212000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2592000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1773000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3294000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	469000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	468000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1570000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1357000	usd
CY2023Q3	us-gaap	Marketing Expense MarketingExpense	297000	usd
CY2022Q3	us-gaap	Marketing Expense MarketingExpense	24000	usd
	us-gaap	Marketing Expense MarketingExpense	631000	usd
	us-gaap	Marketing Expense MarketingExpense	205000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	431000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	384000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1448000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1138000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1197000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-876000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3649000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2700000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	18000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	20000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	11000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	56000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1179000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-856000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3638000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2644000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68836598	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68836598	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68720970	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68720970	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69233573	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69233573	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67186877	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67186877	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2592000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1000000	usd
	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	1258000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3638000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1212000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2371000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	3625000	usd
	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	226000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2644000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	3578000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	2008000	usd
CY2023Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	383000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1179000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	1212000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	3885000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	425000	usd
CY2022Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	124000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-856000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	3578000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3638000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2644000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1258000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	226000	usd
	us-gaap	Depreciation Depreciation	17000	usd
	us-gaap	Depreciation Depreciation	10000	usd
	IRME	Increase Decrease In Accrued Financial Expenses IncreaseDecreaseInAccruedFinancialExpenses	11000	usd
	IRME	Increase Decrease In Accrued Financial Expenses IncreaseDecreaseInAccruedFinancialExpenses	18000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	28000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-76000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-154000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2478000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2596000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	48000	usd
	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	9000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-57000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1000000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3625000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3625000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1478000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	971000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3002000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2815000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1524000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3786000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_806_eus-gaap--NatureOfOperations_zAVM3UGYQzb8" style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_826_z8K6ZQ0zyW0l">General</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description of Business</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IR-Med, Inc. (OTC QB: IRME, hereinafter: the “Company”) was incorporated in Nevada in 2007 and is a holding company. It also operates through IR. Med Ltd., the Company’s wholly owned subsidiary (the “Subsidiary”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registered office of IR-Med, Inc. and the corporate headquarters and research facility of the Subsidiary are located in Rosh Pina, Israel.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a development stage medical device. company developing its technology through its Subsidiary and is utilizing Infra-Red light spectroscopy (IR), combined with an Artificial Intelligence (AI) technology platform, to develop non-invasive devices for various medical indications, by detecting and measuring various biomarkers and molecules in the blood and in human tissue in real-time. The initial product candidates which are currently in various stages of development are non-invasive, user friendly and designed to address the medical needs of large and growing target patient groups by offering earlier and more accurate information for detection, which is expected to reduce healthcare expenses, reduce widespread reliance on antibiotics administration, and other interventional options, and optimize the delivery of targeted medical services and, as a result, improve the efficacy and safety of administered treatments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going Concern</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. However, substantial doubt about the Company’s ability to continue as a going concern exists.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is in its development stage and does not expect to generate significant revenue until such time as the Company shall have completed the design and development of its initial product candidate and obtained the requisite approvals to market its products. During the nine months ended September 30, 2023, the Company has incurred losses of $ <span id="xdx_901_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20230101__20230930_z9fFjhsA0suf" title="Net losses">3,638</span> thousand and had a negative cash flow from operating activities of $<span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20230101__20230930_z0ilrPUE5Ce1" title="Cash flow from operating activities net">2,478</span> thousand. The accumulated deficit as of September 30, 2023, is $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20230930_zoj67TIZRwI9" title="Accumulated deficit">13,568</span> thousand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management’s plans regarding these matters include continued development and marketing of the Company’s products, as well as seeking additional financing arrangements. Although management continues to pursue these plans, there is no assurance that the Company will be successful in raising the needed capital from revenues or financing on commercially acceptable terms. See also note 6 to these financial statements regarding the Iron Swords War (as defined herein) which has caused additional difficulties in management’s efforts to seek additional financing arrangements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 12, 2023, the Company entered into a subscription agreement with one investor pursuant to which the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230611__20230612__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zn6udTnsmESg">1,000,000</span> shares of its common stock at a per share price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20230612__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z14oR1Ciz0P8">1.00</span>, and warrants to purchase up to an additional <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230612__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zGFoFNizpXx5">1,000,000</span> shares of common stock at a per share exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230612__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zqh37aPTcmNa">1.40</span>. The warrants expire on the third anniversary from the date of issuance of the warrant to the holder. The Company is entitled to accelerate the warrant exercise period for all or a part of the then outstanding warrants by written notice to the holders if the publicly traded price of the Company’s common stock equals or exceeds $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20230612__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--RangeAxis__srt--MaximumMember_z0HRmyqd3yE">2.50</span> per share (which amount may be adjusted for certain capital events, such as stock splits, as described herein) and the corresponding average daily trading volume during such period shall equal or exceed <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230612__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--RangeAxis__srt--MaximumMember_zIHfFaCAJtd3">75,000</span> shares, in each case for the preceding forty (<span id="xdx_90C_ecustom--TradingDays_dtD_c20230611__20230612__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkVAA4N5R3Ac" title="Trading days">40</span>) consecutive trading days. The Company received aggregate proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromWarrantExercises_c20230611__20230612__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z3YGJ4NZo2q1">1,000,000</span> from this financing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the Company’s financial condition, substantial doubt exists that the Company will be able to continue as a going concern for one year from the issuance date of these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company were unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IR-Med, Inc.</span></p> <div style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to the Interim Unaudited Condensed Consolidated Financial Statements</b></span></p> </div> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
	us-gaap	Net Income Loss NetIncomeLoss	-3638000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2478000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13568000	usd
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	15744175	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	11601688	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	1258000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	226000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	383000	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	124000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1258000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	226000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.16	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9537	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8277	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.4257	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0361	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0416	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0017	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0263	pure
CY2023Q2	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	2100000	usd

Files In Submission

Name	View Source	Status
irme-20230930_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-041051-index-headers.html	Edgar Link	pending
0001493152-23-041051-index.html	Edgar Link	pending
0001493152-23-041051.txt	Edgar Link	pending
0001493152-23-041051-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
irme-20230930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
irme-20230930_def.xml	Edgar Link	unprocessable
irme-20230930_lab.xml	Edgar Link	unprocessable
irme-20230930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IRME
IR-Med, Inc. Stock $irme

2023 Q4 Form 10-Q Financial Statement

#000149315223041051 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRME IR-Med, Inc. Stock $irme

2023 Q4 Form 10-Q Financial Statement

#000149315223041051 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRME
IR-Med, Inc. Stock $irme